GSK stock steadies as Tivicay approval adds support

GSK stock is trading in the low $50s as a US FDA approval for Tivicay PD adds fresh support to the HIV franchise. Recent trading and earnings data keep the valuation picture grounded.

GSK plc (GB0009252882) stock closed at $51.43 on August 26, 2026, and a pre-market quote of $51.28 was reported the next morning, while market capitalization was listed at $102.04 billion and the 52-week range stood at $38.63 to $61.69. The shares are being weighed against a late-August regulatory gain for Tivicay PD and a second-quarter earnings print that still frames the valuation debate.

Regulatory lift

A late-August update reported US Food and Drug Administration approval for Tivicay PD in younger pediatric HIV patients, extending a franchise that remains important to GSK's HIV business. The same update placed the shares at $51.43 on August 26, 2026, after a 1.23 percent daily decline, and said the stock later indicated $51.28 in pre-market trading.

That move matters because the market value is large enough that even a small change in the share price can shift equity capitalization by billions of dollars. In late July 2026, the company was cited at $108.77 billion in market value, compared with $105.11 billion a day earlier, showing how sensitive the stock remains to modest price changes.

Earnings still matter

The latest reported quarter in the search results was the period ended July 2026, when GSK reported core EPS of $1.36 and revenue of $11.28 billion. MarketBeat said the EPS topped the consensus estimate of $1.27 by $0.09, and its page also described revenue as up 5.3 percent year over year.

Guidance remains part of the backdrop as well. A recent market note said GSK reaffirmed 2026 expectations for 3 percent to 5 percent turnover growth and 7 percent to 9 percent core EPS growth, which gives investors a clean comparison point against the $1.36 quarterly core EPS and the $11.28 billion in revenue already reported for July 2026.

What investors are watching

Consensus on the stock points to a hold view, with a target of $53.00 and a potential upside of 5.0 percent from the MarketBeat snapshot. That keeps attention on whether pipeline news, HIV label expansion and vaccines can do more work than the current range suggests.

Tivicay PD

Tivicay PD is the pediatric formulation of dolutegravir, a key HIV medicine designed for children who need dispersible tablets and weight-based dosing. The approval extends the product's reach in a category where long-duration treatment can support recurring revenue over time.

GSK stock in late August

GSK stock is still centered in the low $50s, with a documented close of $51.43 on August 26, 2026 and a market cap of $102.04 billion in the latest quote snapshot. The 52-week band of $38.63 to $61.69 leaves room for a wider move if regulatory wins and the next reporting period both stay constructive.

Fact box

Company: GSK plc
ISIN: GB0009252882
Ticker: GSK
Exchange: New York Stock Exchange (ADS), London Stock Exchange (primary listing)
Price (as of August 26, 2026, 4:00 p.m. ET): $51.43 USD
Market cap: $102.04 billion (as of August 28, 2026)
Sector / Industry: Healthcare / Pharmaceuticals and biotechnology
Index membership: FTSE 100

Read more

More on GSK stock and the latest company context.